Kiniksa Pharmaceuticals International, plc
KNSA
$31.98
$1.725.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 44.34% | 72.54% | 46.93% | 67.37% | 51.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.34% | 72.54% | 46.93% | 67.37% | 51.99% |
| Cost of Revenue | 67.76% | 96.46% | 149.16% | 87.19% | 95.23% |
| Gross Profit | 29.39% | 57.05% | -0.74% | 54.50% | 33.15% |
| SG&A Expenses | 10.54% | 12.53% | 10.33% | 34.61% | 45.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.65% | 29.16% | 70.24% | 56.30% | 45.72% |
| Operating Income | 17,330.77% | 180.23% | -23,925.93% | 11.61% | 96.29% |
| Income Before Tax | 892.93% | 209.03% | -793.02% | 15.27% | 285.96% |
| Income Tax Expenses | -18.79% | 104.96% | 64.49% | 2.54% | 138.32% |
| Earnings from Continuing Operations | 556.29% | 148.23% | -135.22% | 8.39% | -126.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 556.29% | 148.23% | -135.22% | 8.39% | -126.10% |
| EBIT | 17,330.77% | 180.23% | -23,925.93% | 11.61% | 96.29% |
| EBITDA | 6,455.27% | 184.70% | -3,143.32% | 10.32% | 112.26% |
| EPS Basic | 541.45% | 146.89% | -134.27% | 10.33% | -125.69% |
| Normalized Basic EPS | 859.11% | 206.02% | -772.94% | 17.17% | 282.88% |
| EPS Diluted | 483.33% | 143.89% | -134.96% | 10.33% | -128.57% |
| Normalized Diluted EPS | 803.45% | 201.19% | -795.26% | 17.17% | 287.96% |
| Average Basic Shares Outstanding | 3.43% | 2.85% | 2.77% | 2.20% | 1.55% |
| Average Diluted Shares Outstanding | 9.77% | 7.80% | -0.47% | 2.20% | -0.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |